 | • レポートコード：MRC2-11QY12571 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は黄斑浮腫治療薬のグローバル市場について調査・分析したレポートです。種類別（レーザー治療、抗VEGF注射、抗炎症治療、硝子体切除術）市場規模、用途別（嚢胞性黄斑浮腫（CME）、糖尿病性黄斑浮腫（DME））市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別黄斑浮腫治療薬の競争状況、市場シェア ・世界の黄斑浮腫治療薬市場：種類別市場規模 2015年-2020年（レーザー治療、抗VEGF注射、抗炎症治療、硝子体切除術） ・世界の黄斑浮腫治療薬市場：種類別市場規模予測 2021年-2026年（レーザー治療、抗VEGF注射、抗炎症治療、硝子体切除術） ・世界の黄斑浮腫治療薬市場：用途別市場規模 2015年-2020年（嚢胞性黄斑浮腫（CME）、糖尿病性黄斑浮腫（DME）） ・世界の黄斑浮腫治療薬市場：用途別市場規模予測 2021年-2026年（嚢胞性黄斑浮腫（CME）、糖尿病性黄斑浮腫（DME）） ・北米の黄斑浮腫治療薬市場分析：米国、カナダ ・ヨーロッパの黄斑浮腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの黄斑浮腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の黄斑浮腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの黄斑浮腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Allergan、Novartis、Roche、Regeneron Pharmaceuticals、Pfizer、Bayer、Boehringer Ingelheim、Bausch & Lomb、Aciont、ActiveSite Pharmaceuticals、Adverum Biotechnologies、Aerpio Therapeutics、Ampio Pharmaceuticals、Araim Pharmaceuticals、Astellas Pharma ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Macula is oval yellowish area surrounding the center of retina in the eye. Macular edema is the state when fluid and protein start accumulating under macula resulting swelling in the eye. Due to this swelling, central vision of eye get distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME).
The market of macular edema is dominated by North America which is followed by Europe due tremendous number of population suffering from diabetics. Asia Pacific region have also shown faster rate of increases of macular edema therapeutics market. While Africa and Australia have low market of Macular edema. In Asia pacific region India, China and Brazil have shown emerging growth in the global market of macular edema therapeutics.
Market Analysis and Insights: Global Macular Edema Therapeutics Market
The global Macular Edema Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Macular Edema Therapeutics Scope and Market Size
Macular Edema Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Macular Edema Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Allergan
Novartis
Roche
Regeneron Pharmaceuticals
Pfizer
Bayer
Boehringer Ingelheim
Bausch & Lomb
Aciont
ActiveSite Pharmaceuticals
Adverum Biotechnologies
Aerpio Therapeutics
Ampio Pharmaceuticals
Araim Pharmaceuticals
Astellas Pharma
Market segment by Type, the product can be split into
Laser Treatment
Anti-VEGF Injection
Anti-Inflammatory Treatment
Vitrectomy
Market segment by Application, split into
Cystoid Macular Edema (CME)
Diabetic Macular Edema(DME)
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Macular Edema Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Macular Edema Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Laser Treatment
1.4.3 Anti-VEGF Injection
1.4.4 Anti-Inflammatory Treatment
1.4.5 Vitrectomy
1.5 Market by Application
1.5.1 Global Macular Edema Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Cystoid Macular Edema (CME)
1.5.3 Diabetic Macular Edema(DME)
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Macular Edema Therapeutics Market Perspective (2015-2026)
2.2 Global Macular Edema Therapeutics Growth Trends by Regions
2.2.1 Macular Edema Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Macular Edema Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Macular Edema Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Macular Edema Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Macular Edema Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Macular Edema Therapeutics Players by Market Size
3.1.1 Global Top Macular Edema Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Macular Edema Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Macular Edema Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Macular Edema Therapeutics Market Concentration Ratio
3.2.1 Global Macular Edema Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Macular Edema Therapeutics Revenue in 2019
3.3 Macular Edema Therapeutics Key Players Head office and Area Served
3.4 Key Players Macular Edema Therapeutics Product Solution and Service
3.5 Date of Enter into Macular Edema Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Macular Edema Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Macular Edema Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Macular Edema Therapeutics Market Size by Application (2015-2020)
5.2 Global Macular Edema Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Macular Edema Therapeutics Market Size (2015-2020)
6.2 Macular Edema Therapeutics Key Players in North America (2019-2020)
6.3 North America Macular Edema Therapeutics Market Size by Type (2015-2020)
6.4 North America Macular Edema Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Macular Edema Therapeutics Market Size (2015-2020)
7.2 Macular Edema Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Macular Edema Therapeutics Market Size by Type (2015-2020)
7.4 Europe Macular Edema Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Macular Edema Therapeutics Market Size (2015-2020)
8.2 Macular Edema Therapeutics Key Players in China (2019-2020)
8.3 China Macular Edema Therapeutics Market Size by Type (2015-2020)
8.4 China Macular Edema Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Macular Edema Therapeutics Market Size (2015-2020)
9.2 Macular Edema Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Macular Edema Therapeutics Market Size by Type (2015-2020)
9.4 Japan Macular Edema Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Macular Edema Therapeutics Market Size (2015-2020)
10.2 Macular Edema Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Macular Edema Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Macular Edema Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Macular Edema Therapeutics Market Size (2015-2020)
11.2 Macular Edema Therapeutics Key Players in India (2019-2020)
11.3 India Macular Edema Therapeutics Market Size by Type (2015-2020)
11.4 India Macular Edema Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Macular Edema Therapeutics Market Size (2015-2020)
12.2 Macular Edema Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Macular Edema Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Macular Edema Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Allergan
13.1.1 Allergan Company Details
13.1.2 Allergan Business Overview
13.1.3 Allergan Macular Edema Therapeutics Introduction
13.1.4 Allergan Revenue in Macular Edema Therapeutics Business (2015-2020))
13.1.5 Allergan Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Macular Edema Therapeutics Introduction
13.2.4 Novartis Revenue in Macular Edema Therapeutics Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Macular Edema Therapeutics Introduction
13.3.4 Roche Revenue in Macular Edema Therapeutics Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Regeneron Pharmaceuticals
13.4.1 Regeneron Pharmaceuticals Company Details
13.4.2 Regeneron Pharmaceuticals Business Overview
13.4.3 Regeneron Pharmaceuticals Macular Edema Therapeutics Introduction
13.4.4 Regeneron Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020)
13.4.5 Regeneron Pharmaceuticals Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview
13.5.3 Pfizer Macular Edema Therapeutics Introduction
13.5.4 Pfizer Revenue in Macular Edema Therapeutics Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 Bayer
13.6.1 Bayer Company Details
13.6.2 Bayer Business Overview
13.6.3 Bayer Macular Edema Therapeutics Introduction
13.6.4 Bayer Revenue in Macular Edema Therapeutics Business (2015-2020)
13.6.5 Bayer Recent Development
13.7 Boehringer Ingelheim
13.7.1 Boehringer Ingelheim Company Details
13.7.2 Boehringer Ingelheim Business Overview
13.7.3 Boehringer Ingelheim Macular Edema Therapeutics Introduction
13.7.4 Boehringer Ingelheim Revenue in Macular Edema Therapeutics Business (2015-2020)
13.7.5 Boehringer Ingelheim Recent Development
13.8 Bausch & Lomb
13.8.1 Bausch & Lomb Company Details
13.8.2 Bausch & Lomb Business Overview
13.8.3 Bausch & Lomb Macular Edema Therapeutics Introduction
13.8.4 Bausch & Lomb Revenue in Macular Edema Therapeutics Business (2015-2020)
13.8.5 Bausch & Lomb Recent Development
13.9 Aciont
13.9.1 Aciont Company Details
13.9.2 Aciont Business Overview
13.9.3 Aciont Macular Edema Therapeutics Introduction
13.9.4 Aciont Revenue in Macular Edema Therapeutics Business (2015-2020)
13.9.5 Aciont Recent Development
13.10 ActiveSite Pharmaceuticals
13.10.1 ActiveSite Pharmaceuticals Company Details
13.10.2 ActiveSite Pharmaceuticals Business Overview
13.10.3 ActiveSite Pharmaceuticals Macular Edema Therapeutics Introduction
13.10.4 ActiveSite Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020)
13.10.5 ActiveSite Pharmaceuticals Recent Development
13.11 Adverum Biotechnologies
10.11.1 Adverum Biotechnologies Company Details
10.11.2 Adverum Biotechnologies Business Overview
10.11.3 Adverum Biotechnologies Macular Edema Therapeutics Introduction
10.11.4 Adverum Biotechnologies Revenue in Macular Edema Therapeutics Business (2015-2020)
10.11.5 Adverum Biotechnologies Recent Development
13.12 Aerpio Therapeutics
10.12.1 Aerpio Therapeutics Company Details
10.12.2 Aerpio Therapeutics Business Overview
10.12.3 Aerpio Therapeutics Macular Edema Therapeutics Introduction
10.12.4 Aerpio Therapeutics Revenue in Macular Edema Therapeutics Business (2015-2020)
10.12.5 Aerpio Therapeutics Recent Development
13.13 Ampio Pharmaceuticals
10.13.1 Ampio Pharmaceuticals Company Details
10.13.2 Ampio Pharmaceuticals Business Overview
10.13.3 Ampio Pharmaceuticals Macular Edema Therapeutics Introduction
10.13.4 Ampio Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020)
10.13.5 Ampio Pharmaceuticals Recent Development
13.14 Araim Pharmaceuticals
10.14.1 Araim Pharmaceuticals Company Details
10.14.2 Araim Pharmaceuticals Business Overview
10.14.3 Araim Pharmaceuticals Macular Edema Therapeutics Introduction
10.14.4 Araim Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020)
10.14.5 Araim Pharmaceuticals Recent Development
13.15 Astellas Pharma
10.15.1 Astellas Pharma Company Details
10.15.2 Astellas Pharma Business Overview
10.15.3 Astellas Pharma Macular Edema Therapeutics Introduction
10.15.4 Astellas Pharma Revenue in Macular Edema Therapeutics Business (2015-2020)
10.15.5 Astellas Pharma Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Macular Edema Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Macular Edema Therapeutics Revenue
Table 3. Ranking of Global Top Macular Edema Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Macular Edema Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Laser Treatment
Table 6. Key Players of Anti-VEGF Injection
Table 7. Key Players of Anti-Inflammatory Treatment
Table 8. Key Players of Vitrectomy
Table 9. Global Macular Edema Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Macular Edema Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Macular Edema Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Macular Edema Therapeutics Market Share by Regions (2015-2020)
Table 13. Global Macular Edema Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Macular Edema Therapeutics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Macular Edema Therapeutics Market Growth Strategy
Table 19. Main Points Interviewed from Key Macular Edema Therapeutics Players
Table 20. Global Macular Edema Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Macular Edema Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Macular Edema Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Edema Therapeutics as of 2019)
Table 23. Global Macular Edema Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Macular Edema Therapeutics Product Solution and Service
Table 26. Date of Enter into Macular Edema Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Macular Edema Therapeutics Market Size Share by Type (2015-2020)
Table 30. Global Macular Edema Therapeutics Revenue Market Share by Type (2021-2026)
Table 31. Global Macular Edema Therapeutics Market Size Share by Application (2015-2020)
Table 32. Global Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Macular Edema Therapeutics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Macular Edema Therapeutics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Macular Edema Therapeutics Market Share (2019-2020)
Table 36. North America Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Macular Edema Therapeutics Market Share by Type (2015-2020)
Table 38. North America Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Macular Edema Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Key Players Macular Edema Therapeutics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Macular Edema Therapeutics Market Share (2019-2020)
Table 42. Europe Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Macular Edema Therapeutics Market Share by Type (2015-2020)
Table 44. Europe Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Macular Edema Therapeutics Market Share by Application (2015-2020)
Table 46. China Key Players Macular Edema Therapeutics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Macular Edema Therapeutics Market Share (2019-2020)
Table 48. China Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. China Macular Edema Therapeutics Market Share by Type (2015-2020)
Table 50. China Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. China Macular Edema Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Key Players Macular Edema Therapeutics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Macular Edema Therapeutics Market Share (2019-2020)
Table 54. Japan Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Macular Edema Therapeutics Market Share by Type (2015-2020)
Table 56. Japan Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Macular Edema Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Macular Edema Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Macular Edema Therapeutics Market Share (2019-2020)
Table 60. Southeast Asia Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Macular Edema Therapeutics Market Share by Type (2015-2020)
Table 62. Southeast Asia Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Macular Edema Therapeutics Market Share by Application (2015-2020)
Table 64. India Key Players Macular Edema Therapeutics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Macular Edema Therapeutics Market Share (2019-2020)
Table 66. India Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. India Macular Edema Therapeutics Market Share by Type (2015-2020)
Table 68. India Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. India Macular Edema Therapeutics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Macular Edema Therapeutics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Macular Edema Therapeutics Market Share (2019-2020)
Table 72. Central & South America Macular Edema Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Macular Edema Therapeutics Market Share by Type (2015-2020)
Table 74. Central & South America Macular Edema Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Macular Edema Therapeutics Market Share by Application (2015-2020)
Table 76. Allergan Company Details
Table 77. Allergan Business Overview
Table 78. Allergan Product
Table 79. Allergan Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 80. Allergan Recent Development
Table 81. Novartis Company Details
Table 82. Novartis Business Overview
Table 83. Novartis Product
Table 84. Novartis Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 85. Novartis Recent Development
Table 86. Roche Company Details
Table 87. Roche Business Overview
Table 88. Roche Product
Table 89. Roche Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 90. Roche Recent Development
Table 91. Regeneron Pharmaceuticals Company Details
Table 92. Regeneron Pharmaceuticals Business Overview
Table 93. Regeneron Pharmaceuticals Product
Table 94. Regeneron Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 95. Regeneron Pharmaceuticals Recent Development
Table 96. Pfizer Company Details
Table 97. Pfizer Business Overview
Table 98. Pfizer Product
Table 99. Pfizer Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 100. Pfizer Recent Development
Table 101. Bayer Company Details
Table 102. Bayer Business Overview
Table 103. Bayer Product
Table 104. Bayer Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 105. Bayer Recent Development
Table 106. Boehringer Ingelheim Company Details
Table 107. Boehringer Ingelheim Business Overview
Table 108. Boehringer Ingelheim Product
Table 109. Boehringer Ingelheim Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 110. Boehringer Ingelheim Recent Development
Table 111. Bausch & Lomb Business Overview
Table 112. Bausch & Lomb Product
Table 113. Bausch & Lomb Company Details
Table 114. Bausch & Lomb Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 115. Bausch & Lomb Recent Development
Table 116. Aciont Company Details
Table 117. Aciont Business Overview
Table 118. Aciont Product
Table 119. Aciont Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 120. Aciont Recent Development
Table 121. ActiveSite Pharmaceuticals Company Details
Table 122. ActiveSite Pharmaceuticals Business Overview
Table 123. ActiveSite Pharmaceuticals Product
Table 124. ActiveSite Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 125. ActiveSite Pharmaceuticals Recent Development
Table 126. Adverum Biotechnologies Company Details
Table 127. Adverum Biotechnologies Business Overview
Table 128. Adverum Biotechnologies Product
Table 129. Adverum Biotechnologies Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 130. Adverum Biotechnologies Recent Development
Table 131. Aerpio Therapeutics Company Details
Table 132. Aerpio Therapeutics Business Overview
Table 133. Aerpio Therapeutics Product
Table 134. Aerpio Therapeutics Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 135. Aerpio Therapeutics Recent Development
Table 136. Ampio Pharmaceuticals Company Details
Table 137. Ampio Pharmaceuticals Business Overview
Table 138. Ampio Pharmaceuticals Product
Table 139. Ampio Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 140. Ampio Pharmaceuticals Recent Development
Table 141. Araim Pharmaceuticals Company Details
Table 142. Araim Pharmaceuticals Business Overview
Table 143. Araim Pharmaceuticals Product
Table 144. Araim Pharmaceuticals Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 145. Araim Pharmaceuticals Recent Development
Table 146. Astellas Pharma Company Details
Table 147. Astellas Pharma Business Overview
Table 148. Astellas Pharma Product
Table 149. Astellas Pharma Revenue in Macular Edema Therapeutics Business (2015-2020) (Million US$)
Table 150. Astellas Pharma Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Macular Edema Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Laser Treatment Features
Figure 3. Anti-VEGF Injection Features
Figure 4. Anti-Inflammatory Treatment Features
Figure 5. Vitrectomy Features
Figure 6. Global Macular Edema Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Cystoid Macular Edema (CME) Case Studies
Figure 8. Diabetic Macular Edema(DME) Case Studies
Figure 9. Macular Edema Therapeutics Report Years Considered
Figure 10. Global Macular Edema Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Macular Edema Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Macular Edema Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Macular Edema Therapeutics Market Share by Players in 2019
Figure 15. Global Top Macular Edema Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Edema Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Macular Edema Therapeutics Revenue in 2019
Figure 17. North America Macular Edema Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Macular Edema Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Macular Edema Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Macular Edema Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Macular Edema Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Macular Edema Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Macular Edema Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
糖尿病性黄斑浮腫治療の世界市場（～2026年） Diabetic macular edema (DME) is characterized by accumulation of fluid in the macula – a part of retina responsible for vision. Accumulation may cause by leakage of plasma constituents into the surrounding, consequently leading to edema. Increasing prevalence of diabetes in the prime factor driving …- 糖尿病性黄斑浮腫治療薬の世界市場（～2026年） Market Analysis and Insights: Global Diabetic Macular Edema Drug Market The global Diabetic Macular Edema Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Diabetic Macular Edema Drug Scope and Market Size Diabetic …
- 嚢胞様黄斑浮腫の世界市場（～2026年） Cystoid macular edema (CME) also known as Irvine Gass Syndrome is a painless disorder affecting the central retina or macula. This condition is characterized by multiple cysts like areas of fluid in the macula causing retinal swelling or edema. CME is the retinal thickening of macula due to disrupti…
- 若年性黄斑変性症治療の世界市場（～2026年） Market Analysis and Insights: Global Juvenile Macular Degeneration Treatment Market The global Juvenile Macular Degeneration Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Juvenile Macular Degeneration Treat…
- 加齢黄斑変性症（AMD）遺伝子治療の世界市場（～2026年） Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is dire…